Noronha Vanita, Burtness Barbara, Murren John, Duffy Thomas P
Mid Valley Oncology/Hematology, P.C., 407 Gidney Avenue, Newburgh, NY 12550, USA.
Clin Colorectal Cancer. 2005 Nov;5(4):283-6. doi: 10.3816/ccc.2005.n.041.
We report a case of a 59-year-old woman with metastatic carcinoma of the ileocecal region who received FOLFOX(oxaliplatin/leucovorin/5-fluorouracil) and bevacizumab therapy and exhibited a partial remission with minimal side effects. She developed a mild self-limited episode of immune-mediated hemolytic anemia during her 16th cycle of chemotherapy, which precluded her from receiving further oxaliplatin. We review the literature on oxaliplatin-induced immune-mediated hemolysis, including its mechanism, presenting symptoms, laboratory features, management, and implications for future therapy.
